GLP1R and type 2 diabetes mellitus: In particular, the 2019 European Society of Cardiology (ESC) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases, developed in collaboration with the European Association for the Study of Diabetes (EASD), advise GLP1-RAs in patients with T2D and CV disease or at high CV risk to reduce cardiovascular events (class of recommendation I, level of evidence A) [15].